Lim Joo Han, Kim Hoon, Choi Woong Gil, Lee Moon Hee
Department of Internal Medicine, Inha University School of Medicine, Incheon, Korea.
J Cancer Res Ther. 2010 Oct-Dec;6(4):546-8. doi: 10.4103/0973-1482.77066.
Currently, FOLFOX regimen has been widely used as an effective approach for treating many advanced GI tract cancers. Toxicity induced by oxaliplatin has been well known and mostly moderate and manageable. Gastrointestinal, hematological and neurosensory toxicities are the most common. However, information concerning the pulmonary toxicity of this regimen is very limited and only a few cases of severe lung toxicity associated with FOLFOX chemotherapy have been reported. Here, we report a fatal case of interstitial lung disease which was associated with FOLFOX chemotherapy in metastatic advanced gastric cancer. The patient expired from progressive respiratory failure. This case suggests that FOLFOX-induced interstitial lung disease should be considered in the differential diagnosis of new lung lesions in patients who are treated with FOLFOX chemotherapy. And further investigations of possible association that may lead to acute respiratory failure are warranted.
目前，FOLFOX方案已被广泛用作治疗多种晚期胃肠道癌症的有效方法。奥沙利铂引起的毒性已为人熟知，大多为中度且可控。胃肠道、血液学和神经感觉毒性最为常见。然而，关于该方案肺部毒性的信息非常有限，仅有少数与FOLFOX化疗相关的严重肺部毒性病例报道。在此，我们报告1例与FOLFOX化疗相关的转移性晚期胃癌间质性肺疾病致死病例。患者死于进行性呼吸衰竭。该病例提示，在对接受FOLFOX化疗患者新发肺部病变进行鉴别诊断时应考虑FOLFOX诱导的间质性肺疾病。有必要对可能导致急性呼吸衰竭的关联因素做进一步研究。
